These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 35657046)
1. Discovery of Polo-like Kinase 4 Inhibitors for the Treatment of Cancer: A Mini Patent Review. Shu Y; Liu Y; Bian S; Xie Z; Liao C Mini Rev Med Chem; 2023; 23(1):67-79. PubMed ID: 35657046 [TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of targeting polo-like kinase 4. Lei Q; Yu Q; Yang N; Xiao Z; Song C; Zhang R; Yang S; Liu Z; Deng H Eur J Med Chem; 2024 Feb; 265():116115. PubMed ID: 38199166 [TBL] [Abstract][Full Text] [Related]
3. PLK4: a promising target for cancer therapy. Zhao Y; Wang X J Cancer Res Clin Oncol; 2019 Oct; 145(10):2413-2422. PubMed ID: 31492983 [TBL] [Abstract][Full Text] [Related]
4. Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present). Bian S; Zhang R; Nie J; Zhu M; Xie Z; Liao C; Wang Q Expert Opin Ther Pat; 2024 Sep; 34(9):789-806. PubMed ID: 38994687 [TBL] [Abstract][Full Text] [Related]
5. Non-mitotic functions of polo-like kinases in cancer cells. Raab CA; Raab M; Becker S; Strebhardt K Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265 [TBL] [Abstract][Full Text] [Related]
6. Role of Polo-Like Kinase 4 (PLK4) in Epithelial Cancers and Recent Progress in its Small Molecule Targeting for Cancer Management. Garvey DR; Chhabra G; Ndiaye MA; Ahmad N Mol Cancer Ther; 2021 Apr; 20(4):632-640. PubMed ID: 33402398 [TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Kawakami M; Mustachio LM; Zheng L; Chen Y; Rodriguez-Canales J; Mino B; Kurie JM; Roszik J; Villalobos PA; Thu KL; Silvester J; Cescon DW; Wistuba II; Mak TW; Liu X; Dmitrovsky E Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1913-1918. PubMed ID: 29434041 [TBL] [Abstract][Full Text] [Related]
8. Autoinhibition and relief mechanism for Polo-like kinase 4. Klebba JE; Buster DW; McLamarrah TA; Rusan NM; Rogers GC Proc Natl Acad Sci U S A; 2015 Feb; 112(7):E657-66. PubMed ID: 25646492 [TBL] [Abstract][Full Text] [Related]
9. Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy. Zhang X; Wei C; Liang H; Han L Front Oncol; 2021; 11():587554. PubMed ID: 33777739 [TBL] [Abstract][Full Text] [Related]
10. Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment. Liu X Transl Oncol; 2015 Jun; 8(3):185-95. PubMed ID: 26055176 [TBL] [Abstract][Full Text] [Related]
11. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents. Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403 [TBL] [Abstract][Full Text] [Related]
12. Functional relationship among PLK2, PLK4 and ROCK2 to induce centrosome amplification. Ling H; Hanashiro K; Luong TH; Benavides L; Fukasawa K Cell Cycle; 2015; 14(4):544-53. PubMed ID: 25590559 [TBL] [Abstract][Full Text] [Related]
13. PLK4: a link between centriole biogenesis and cancer. Maniswami RR; Prashanth S; Karanth AV; Koushik S; Govindaraj H; Mullangi R; Rajagopal S; Jegatheesan SK Expert Opin Ther Targets; 2018 Jan; 22(1):59-73. PubMed ID: 29171762 [TBL] [Abstract][Full Text] [Related]
14. YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect. Lei Q; Xiong L; Xia Y; Feng Z; Gao T; Wei W; Song X; Ye T; Wang N; Peng C; Li Z; Liu Z; Yu L Cell Death Dis; 2018 Oct; 9(11):1066. PubMed ID: 30337519 [TBL] [Abstract][Full Text] [Related]
15. YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects. Zhu Y; Liu Z; Qu Y; Zeng J; Yang M; Li X; Wang Z; Su J; Wang X; Yu L; Wang Y Cancer Chemother Pharmacol; 2020 Jul; 86(1):33-43. PubMed ID: 32519033 [TBL] [Abstract][Full Text] [Related]
16. Autophosphorylation of polo-like kinase 4 and its role in centriole duplication. Sillibourne JE; Tack F; Vloemans N; Boeckx A; Thambirajah S; Bonnet P; Ramaekers FC; Bornens M; Grand-Perret T Mol Biol Cell; 2010 Feb; 21(4):547-61. PubMed ID: 20032307 [TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase 4 kinase activity limits centrosome overduplication by autoregulating its own stability. Holland AJ; Lan W; Niessen S; Hoover H; Cleveland DW J Cell Biol; 2010 Jan; 188(2):191-8. PubMed ID: 20100909 [TBL] [Abstract][Full Text] [Related]
18. Autophosphorylation-induced self-assembly and STIL-dependent reinforcement underlie Plk4's ring-to-dot localization conversion around a human centriole. Park JE; Meng L; Ryu EK; Nagashima K; Baxa U; Bang JK; Lee KS Cell Cycle; 2020 Dec; 19(24):3419-3436. PubMed ID: 33323015 [TBL] [Abstract][Full Text] [Related]
19. Role of Polo-like Kinases Plk1 and Plk4 in the Initiation of Centriole Duplication-Impact on Cancer. Hoffmann I Cells; 2022 Feb; 11(5):. PubMed ID: 35269408 [TBL] [Abstract][Full Text] [Related]